Whitepapers Archives - BLIS Technologies - probiotic manufacturers

WHITEPAPER: ORAL PROBIOTICS FOR BRACES: REDUCING HALITOSIS WITH BLIS M18™

BLIS — Tue, 02 Sep 2025 02:44:33 +0000

Clinical data reveals how a targeted oral probiotic can deliver a breakthrough solution to a common problem—bad breath during orthodontic treatment.

Halitosis is an often-overlooked yet highly disruptive side effect for people wearing braces. With up to 50% of the global population undergoing orthodontic treatment at some stage in life, there’s a growing demand for non-invasive, scientifically credible solutions that go beyond traditional hygiene methods.

In this whitepaper, BLIS Technologies presents in-vitro and clinical trial evidence demonstrating how BLIS M18, a precision probiotic strain of Streptococcus salivarius, effectively reduces volatile sulphur compounds (VSCs)—the primary cause of bad breath in orthodontic patients.

Whether you’re developing new product formats or looking to differentiate with clinically validated oral care innovations, this is essential reading for formulators, brand leaders, and healthcare partners.

What You’ll Learn:

The microbial mechanism behind halitosis in braces wearers
Clinical study results showing sustained reduction in VSCs post-intervention
How BLIS M18 complements oral hygiene by targeting the root microbial cause
Opportunities for product innovation using a science-led, strain-specific probiotic

The post WHITEPAPER: ORAL PROBIOTICS FOR BRACES: REDUCING HALITOSIS WITH BLIS M18™ appeared first on BLIS Technologies - probiotic manufacturers.

A Promising Link between BLIS K12™ and Autoimmune Modulation

BLIS — Mon, 13 Jan 2025 02:54:42 +0000

Autoimmune diseases affect millions of people worldwide, with conditions like rheumatoid arthritis and psoriasis causing chronic pain and inflammation. Our latest whitepaper, “A Promising Link Between BLIS K12 and Autoimmune Modulation,” delves into the science of probiotics and their role in reshaping the way we manage autoimmune health.

This comprehensive guide offers:

Insights into the connection between oral microbiome dysbiosis and autoimmune diseases.
Research-backed benefits of BLIS K12 in managing autoimmune symptoms.
A deeper understanding of how probiotics could transform the future of autoimmune care.

Download the whitepaper today to uncover the potential of BLIS K12 in improving autoimmune health.

The post A Promising Link between BLIS K12™ and Autoimmune Modulation appeared first on BLIS Technologies - probiotic manufacturers.

WHITEPAPER: Maintaining Periodontal Health to Prevent Systemic Diseases

BLIS — Mon, 07 Oct 2024 01:26:43 +0000

Recent research highlights a growing connection between oral health and systemic diseases, including cognitive, cardiovascular, and even fertility issues. Maintaining periodontal health is crucial for overall wellbeing, potentially lowering the risk of severe conditions such as Alzheimer’s, heart disease, and diabetes.

Our latest whitepaper, Maintaining Periodontal Health to Prevent Systemic Diseases, explores these links in detail, presenting key findings and the role of BLIS M18 oral probiotics in promoting dental and periodontal health.

KEY HIGHLIGHTS:

The connection between periodontal disease and cognitive diseases like Alzheimer’s.
The role of oral health in preventing cardiovascular diseases.
The bi-directional link between periodontal health and diabetes.
New insights into the impact of oral health on fertility.

Discover how BLIS M18 can help protect periodontal health and contribute to the prevention of these systemic conditions.

DOWNLOAD OUR WHITEPAPER BELOW

The post WHITEPAPER: Maintaining Periodontal Health to Prevent Systemic Diseases appeared first on BLIS Technologies - probiotic manufacturers.

WHITEPAPER: REDUCING THE INCIDENCE, DURATION & SEVERITY OF ORAL MUCOSITIS

BLIS — Thu, 06 Jun 2024 00:29:29 +0000

With the global cancer burden escalating, the need for effective supportive care in oncology is more pressing than ever. One of the most common and painful side effects of cancer treatment is mouth sores, medically known as oral mucositis, affecting a significant percentage of patients undergoing chemotherapy and radiotherapy. Recent studies have highlighted the potential of BLIS K12 in providing much-needed relief for this condition.

ORAL MUCOSITIS: A GROWING CONCERN

Oral mucositis, characterized by redness, swelling, and ulcerations of the oral mucosa, is a common side effect of cancer treatments. It can severely impact a patient’s quality of life, often leading to difficulties in swallowing and requiring alternative nutritional support. Currently, about 40% of chemotherapy patients and 30-60% of radiotherapy patients develop this condition, with limited effective treatments available.

DOWNLOAD OUR WHITEPAPER BELOW TO LEARN MORE

The post WHITEPAPER: REDUCING THE INCIDENCE, DURATION & SEVERITY OF ORAL MUCOSITIS appeared first on BLIS Technologies - probiotic manufacturers.

WHITEPAPER: BLIS K12™ ENHANCES IMMUNE DEFENCES AND REDUCES THE SYMPTOMS OF COVID-19

BLIS — Tue, 05 Mar 2024 22:23:27 +0000

In our latest whitepaper, a recent study shows that BLIS K12 stimulates the production of antibodies specific to SARS CoV-2 virus in people that have been vaccinated for COVID-19 and led to accelerated viral clearance.

A second study showed that participants taking BLIS K12 showed reduced symptoms of COVID-19, including lower supplemental oxygen requirements and a lower death rate, compared to patients who received standard care.

The post WHITEPAPER: BLIS K12™ ENHANCES IMMUNE DEFENCES AND REDUCES THE SYMPTOMS OF COVID-19 appeared first on BLIS Technologies - probiotic manufacturers.

WHITEPAPER: STUDIES SHOW BLIS M18™ ENHANCES DENTAL AND GINGIVAL HEALTH

BLIS — Sun, 26 Nov 2023 22:55:52 +0000

In our latest whitepaper, study one shows BLIS M18 significantly reduces gingivitis in young adults by measuring three key clinical markers: the gingival bleeding index, the gingival index and plaque index.

Study two showed that BLIS M18 improved dental health in pre-schoolers that had dental caries, reducing them by 81%.

The post WHITEPAPER: STUDIES SHOW BLIS M18™ ENHANCES DENTAL AND GINGIVAL HEALTH appeared first on BLIS Technologies - probiotic manufacturers.

WHITEPAPER: TARGETING THE SOURCE OF HALITOSIS WITH BLIS K12™

BLIS — Tue, 29 Aug 2023 02:19:56 +0000

In our latest whitepaper, study one shows BLIS K12 reduces VSC – which are unpleasant odorous compounds produced by halitosis-causing bacteria.

Study two shows that when BLIS K12 is used in conjunction with toothbrushing, flossing, and mouthwash, it reduces halitosis over longer periods of time.

The post WHITEPAPER: TARGETING THE SOURCE OF HALITOSIS WITH BLIS K12™ appeared first on BLIS Technologies - probiotic manufacturers.

Whitepaper: How BLIS K12™ stimulates an immune response in times of high need

BLIS — Tue, 11 Jul 2023 04:31:09 +0000

Two new studies have revealed that BLIS K12 stimulates the production of interferon gamma and immunoglobulin A (sIgA) levels in the mouth, which helps to validate the protective effect of BLIS K12 beyond just colonisation of the oral cavity.

The post Whitepaper: How BLIS K12™ stimulates an immune response in times of high need appeared first on BLIS Technologies - probiotic manufacturers.

White Paper: Improving overall Respiratory Health with BLIS K12™

BLIS — Fri, 10 Mar 2023 01:10:39 +0000

Three independent studies reveal continued support that consumption of Streptococcus salivarius (BLIS K12) is beneficial in reducing the frequency and length of respiratory illness caused by both viruses and bacteria.

Complete the following form to download the whitepaper:

The post White Paper: Improving overall Respiratory Health with BLIS K12™ appeared first on BLIS Technologies - probiotic manufacturers.